Risk Factors for De Novo Malignancy Following Lung Transplantation

J. T. Magruder, T. C. Crawford, J. C. Grimm, B. Kim, A. S. Shah, E. L. Bush, R. S. Higgins, C. A. Merlo

Research output: Contribution to journalArticlepeer-review

Abstract

Risk factors for non–skin cancer de novo malignancy (DNM) after lung transplantation have yet to be identified. We queried the United Network for Organ Sharing database for all adult lung transplant patients between 1989 and 2012. Standardized incidence ratios (SIRs) were computed by comparing the data to Surveillance, Epidemiology, and End Results Program data after excluding skin squamous/basal cell carcinomas. We identified 18 093 adult lung transplant patients; median follow-up time was 1086 days (interquartile range 436–2070). DNMs occurred in 1306 patients, with incidences of 1.4%, 4.6%, and 7.9% at 1, 3, and 5 years, respectively. The overall cancer incidence was elevated compared with that of the general US population (SIR 3.26, 95% confidence interval [CI]: 2.95–3.60). The most common cancer types were lung cancer (26.2% of all malignancies, SIR 6.49, 95% CI: 5.04–8.45) and lymphoproliferative disease (20.0%, SIR 14.14, 95% CI: 9.45–22.04). Predictors of DNM following lung transplantation were age (hazard ratio [HR] 1.03, 95% CI: 1.02–1.05, p < 0.001), male gender (HR 1.20, 95% CI: 1.02–1.42, p = 0.03), disease etiology (not cystic fibrosis, idiopathic pulmonary fibrosis or interstitial lung disease, HR 0.59, 95% CI 0.37–0.97, p = 0.04) and single-lung transplantation (HR 1.64, 95% CI: 1.34–2.01, p < 0.001). Significant interactions between donor or recipient smoking and single-lung transplantation were noted. On multivariable survival analysis, DNMs were associated with an increased risk of mortality (HR 1.44, 95% CI: 1.10–1.88, p = 0.009).

Original languageEnglish (US)
Pages (from-to)227-238
Number of pages12
JournalAmerican Journal of Transplantation
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2017

Keywords

  • cancer/malignancy/neoplasia
  • cancer/malignancy/neoplasia: registry/incidence
  • cancer/malignancy/neoplasia: risk factors
  • clinical research/practice
  • health services and outcomes research
  • lung transplantation/pulmonology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Risk Factors for De Novo Malignancy Following Lung Transplantation'. Together they form a unique fingerprint.

Cite this